Author

M. D. Gahete

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Organism:human· 3 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

R. M. Luque· 3 shared A. Ibanez-Costa· 2 shared E. Alors-Perez· 2 shared J. P. Castano· 2 shared R. Blazquez-Encinas· 2 shared S. Pedraza-Arevalo· 2 shared A. Arjona-Sanchez· 1 shared A. C. Fuentes-Fayos· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. M. Luque

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in Pancreatic Ductal Adenocarcinoma

R. Blazquez-Encinas, E. Alors-Perez, M. T. Moreno-Montilla, V. Garcia-Vioque, M. E. Sanchez-Frias, A. Mafficini, J. L. Lopez-Canovas, C. Bousquet, M. D. Gahete, R. T. Lawlor, R. M. Luque, A. Scarpa, A. Arjona-Sanchez, S. Pedraza-Arevalo, A. Ibanez-Costa, J. P. Castano

This study identifies EIF4A3 as an oncogenic factor in PDAC by showing its overexpression correlates with poor prognosis and its role in regulating RNA splicing and tumor growth.

bioRxiv · Dec 7, 2023Cancer Biology

Spliceosomic dysregulation unveils NOVA1 as an actionable therapeutic target in pancreatic neuroendocrine tumors

S. Pedraza-Arevalo, E. Alors-Perez, R. Blazquez-Encinas, A. D. Herrera-Martinez, J. M. Jimenez-Vacas, A. C. Fuentes-Fayos, O. Reyes, S. Ventura, R. Sanchez-Sanchez, R. Ortega-Salas, R. Serrano-Blanch, M. A. Galvez-Moreno, M. D. Gahete, A. Ibanez-Costa, R. M. Luque, J. P. Castano

The paper identifies NOVA1 as a therapeutic target in PanNETs by showing its role in splicing dysregulation, cell proliferation, and drug resistance.

bioRxiv · Feb 9, 2022 · PreprintCancer Biology

The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype

P. B. Thomas, P. L. Jeffery, M. D. Gahete, E. J. Whiteside, C. Walpole, M. L. Maugham, L. Jovanovic, J. H. Gunter, E. D. Williams, C. C. Nelson, A. C. Herington, R. M. Luque, R. N. Veedu, L. K. Chopin, I. Seim

This study identifies GHSROS, a lncRNA upregulated in prostate cancer, which promotes aggressive tumor traits and may be a therapeutic target.

bioRxiv · Jun 26, 2019Cancer Biology